Clinical Trial Update: MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-8228-042 evaluated letermovir for CMV prophylaxis in adult Japanese kidney transplant recipients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Disease
• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus Infection, Cytomegalovirus Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-04-01